All articles by GlobalData 

  1. Approval for Piqray, the first PI3K inhibitor in the treatment of breast cancer

    On 24 May, the US Food and Drug Administration (FDA) approved Piqray (alpelisib), a first-in-class phosphoinositide 3-kinase (PI3K) inhibitor for…
    Read More…

    11 Jun
  2. Premature birth rate remains highest in the US

    In 2015, the US had the highest proportion of live premature births, defined as a gestational age of fewer than…
    Read More…

    11 Jun
  3. Novel HER2 blockade treatments continue to show promise in third-line setting for metastatic breast cancer

    During this year’s American Society of Clinical Oncology (ASCO 2019) meeting in Chicago, two new third-line treatment options were discussed,…
    Read More…

    10 Jun
  4. Takeda’s Ninlaro fails in Phase III trial for treatment of amyloidosis

    Takeda has announced it will be discontinuing its Phase III trial investigating its multiple myeloma drug Ninlaro (ixazomib) for the…
    Read More…

    10 Jun
  5. Will oral therapies be eclipsed by parenteral delivery in the treatment of restless legs syndrome?

    Restless legs syndrome (RLS) is a neurological movement disorder that affects more than 37 million people worldwide. The disorder is…
    Read More…

    10 Jun
  6. What role is there for cannabis use in cancer care?

    With cannabis slowly becoming legalised across North America, physicians meeting recently in Chicago at the American Society of Clinical Oncology…
    Read More…

    10 Jun
  7. Maintenance olaparib trial brings hope to BRCA mutant pancreatic cancer patients

    Pancreatic cancer is known to be one of the few diseases that still has a medium overall survival of less…
    Read More…

    10 Jun
  8. Gene therapy dominated haemophilia B pipeline may see long-term benefits

    Hemophilia B is an inherited deficiency in the clotting factor IX (FIX), which results in poor clotting following minor trauma…
    Read More…

    7 Jun
  9. Sanofi offers more convenient delivery in multiple myeloma treatment with Isatuximab

    One of the most exciting sessions at this year’s American Society of Clinical Oncology (ASCO) meeting last month in Chicago,…
    Read More…

    7 Jun
  10. Pfizer’s Phase III trial of Lyrica in PGTC seizures falls short of endpoint

    A Phase III study assessing the use of Lyrica (pregabalin) as adjunctive therapy for epilepsy patients ages 5 to 65…
    Read More…

    7 Jun
Close
Close
Close

Go Top